
    In re DIET DRUGS (PHENTERMINE/FENFLURAMINE/DEXFEN-FLURAMINE) PRODUCT LIABILITY LITIGATION. Mary Schrodi and/or Estate of Mary Schrodi, Appellant.
    No. 07-2943.
    United States Court of Appeals, Third Circuit.
    Submitted Pursuant to Third Circuit L.A.R. 34.1(a) Oct. 21, 2008.
    Filed Oct. 28, 2008.
    
      Before SMITH, COWEN, Circuit Judges and THOMPSON, District Judge.
    
    
      
       The Honorable Anne E. Thompson, Senior United States District Judge for the District Court of New Jersey, sitting by designation.
    
   OPINION

THOMPSON, District Judge.

I. Background

Appellant Mary Schrodi filed this appeal from the District Court’s May 25, 2007 Pretrial Order, No. 7222, denying Appellant’s claims for benefits under the terms of the Diet Drug Nationwide Class Action Settlement Agreement (“Settlement Agreement”).

In July 2000, Appellant filed a claim with the AHP Settlement Trust (“Trust”), pursuant to the procedures set forth in the Settlement Agreement, for so called Matrix Al, Level II and Level III benefits. Her claim included the statement of an attesting physician diagnosing Appellant with moderate mitral regurgitation based on her echocardiogram, as required for Level II benefits. The attesting physician also reported that Appellant had surgery to repair or replace her aortic valve after having used one of the drugs at issue in this case, serving as the basis of her claim for Level III benefits. Upon review, the Trust’s auditing cardiologist ‘concluded that there was no reasonable medical basis (the standard set out in the Settlement Agreement) for the attesting physician’s finding that Appellant suffered from a moderate mitral regurgitation, finding instead that she only had a mild mitral regurgitation, which is insufficient for Level II benefits. On that basis, the Trust denied Appellant’s claims. Appellant disputed the audit’s adverse finding, and the Trust applied to the District Court for an Order to Show Cause why Appellant’s claim should be paid. The District Court issued the Order and referred the case to a Special Master for further proceedings. The parties submitted statements of the case to the Special Master, and the Special Master appointed a technical advisor to prepare a report for the District Court’s review. Like the auditing cardiologist, the technical advisor concluded that there was no reasonable medical basis for finding that Appellant had moderate mitral regurgitation. Both the parties’ statements and supporting documentation as well as the technical advisor’s report were submitted to the District Court for review in making its decision on the Order to Show Cause. After a thorough review of the record before it, the District Court denied both the Level II and Level III claims, affirming the finding of the Trust with respect to the Level II claim and noting that Appellant’s own attesting physician reported that Appellant did not have even mild aortic regurgitation, an additional element required for Level III benefits.

On appeal, Appellant asserts that (1) the method of interpretation of Appellant’s echocardiogram used by the District Court is medically unsound and (2) the District Court’s use of that method was based on an incorrect interpretation of the Settlement Agreement.

This Court has jurisdiction under 28 U.S.C. § 1291. Because Appellant’s grounds for appeal are based alternatively on issues of fact and interpretation of the Settlement Agreement, our review is under the clearly erroneous standard. See In re Cendant Prides Litig., 233 F.3d 188, 193 (3d Cir.2000) (both issues of fact and interpretation of settlement agreements are reviewed under the clearly erroneous standard).

II. Analysis

With respect to both of Appellant’s arguments, this Court finds that Appellant has failed to show clear error in the District Court’s interpretation or factual findings. The District Court performed a careful and thorough review of the robust record before it, including both parties’ statements and the opinions of the auditing cardiologist, the technical advisor and Appellant’s own attesting physician. This Court thus adopts the District Court’s findings as its own.

III. Conclusion

For the reasons stated above, Appellant’s appeal is denied. 
      
      . The Court will neither repeat the history of the Settlement Agreement in this MDL, as it has been outlined in prior opinions of this Court, see, e.g., In re Diet Drugs Prods. Liab. Litig., 431 F.3d 141 (3d Cir.2005); In re Diet Drugs Prods. Liab. Litig., 282 F.3d 220 (3d Cir.2002), nor summarize the relevant provisions of that agreement, which have been summarized aptly in the District Court's Pretrial Order that is the subject of this appeal.
     
      
      . In further support of the District Court’s findings, see this Court’s recent decision in a related proceeding, In re Diet Drugs Prods. Liab. Litig., 543 F.3d 179, 187-88 (3d Cir. 2008) (agreeing with the District Court that measurement of regurgitant jet in only a single frame of an echocardiogram did not provide a reasonable medical basis for recovering Matrix benefits under the Settlement Agreement).
     